Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
De-ESCALaTE HPV
NL-OMON44755Phase 3Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Jan 2015
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in oropharyngeal squamous cell carcinoma comparing Cetuximab + radiotherapy with Cisplatin + radiotherapy (2 arms). Primary endpoint: Total severe toxicity events. Started Jan 2015; status: active, not recruiting.
02
Drugs
cetuximabcisplatin
03
Conditions
oropharyngeal squamous cell carcinoma
Beyond the preview
Go deeper on NL-OMON44755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44755.